Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 36,462

Document Document Title
WO/2018/130838A1
The present invention relates to 2-thiobenzimidazoles of formula (I) which are of use as fungicides.  
WO/2018/131866A1
The present disclosure relates to an organic electroluminescent device. The organic electroluminescent device of the present disclosure can exhibit low driving voltage, high efficiency and/or long lifespan by comprising a specific combin...  
WO/2018/130863A1
The invention relates to promoting authopagy in the treatment or prevention of autophagy related disorders, such as various forms of cancer; neurodegenerative disease, diabetes, immune deficiency, infection by intracellular microbes, tis...  
WO/2018/127801A1
Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infect...  
WO/2018/129403A1
The present disclosure provides compounds and methods useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preve...  
WO/2018/127207A1
Disclosed in the present invention are a new thiazole compound, particularly a compound represented by formula (I), a pharmaceutical composition thereof and applications thereof in the preparation of drugs for the treatment of diseases r...  
WO/2018/127292A1
The invention relates to a compound (F) (1a) or (1b) wherein R1 is selected from -I, -Br, -CI, -F, C1C6-alkyl, -O(CH2)mCH3, -(CH2)mOCH3, C1C6-haloalkyl, a cycloalkyl, a heterocycle, a aryl or heteroaryl, wherein R2 is selected from H, C1...  
WO/2018/125961A1
The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method o...  
WO/2018/120978A1
The present invention relates to an organic electroluminescence device containing a 1,2,4-triazine based bipolar main material, comprising: a cathode, an anode, and an organic layer; the original layer is one or more of a hole transport ...  
WO/2018/123918A1
Provided is a compound or a salt thereof, represented by the formula shown, which has a RORγt inhibitory effect and is useful as a preventive or therapeutic agent for autoimmune diseases, allergies, and the like.  
WO/2018/121434A1
Disclosed is an aryl hydrocarbon receptor modulator as represented by formula (I) and a pharmaceutically acceptable salt. R' is H, CN, CH2(OH)R0, CmH2m+1, CnH2n-1, CnH2n-3, formula (A), formula (B), or formula (C); two Ra are independent...  
WO/2018/124001A1
The present invention pertains to novel, exceptional low-molecular compounds that specifically antagonize the BMP signaling pathway, and because these compounds can be used to modulate cell growth, differentiation, proliferation, and apo...  
WO/2018/122746A1
The application is directed to compounds of formula (I) : (I), and formula (IA): (IA) and their salts and solvates, wherein R1, R2, R3, R4, R5, n, A1, A2, A3, and Y are as set forth in the specification, as well as to a method for their ...  
WO/2018/121610A1
Provided are a compound as shown in general formula I, a pharmaceutically acceptable salt, an isomer and a solvate thereof, or a compound obtained through the substitution of any atom in the compound of formula I with an isotope thereof,...  
WO/2018/122550A1
A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein: • B is an aryl or heteroaryl group optionally substituted by one or more R10 groups; and * X is sele...  
WO/2018/120979A1
The present application relates to a 1,2,4-triazine based bipolar main material and an application thereof. The 1,2,4-triazine based bipolar main material has a compound having the structure of formula (I), wherein R1-R6 represent substi...  
WO/2018/123625A1
A purpose of the present invention is to provide a polymerizable compound that can be used in the production of an optical film or similar with good reverse wavelength dispersion. This polymerizable compound is indicated by formula (I). ...  
WO/2018/121267A1
A [1,3]thiazol-2-amine compound, an application, and a pharmaceutical composition. The present invention belongs to the field of BACE inhibitors. The [1,3]thiazol-2-amine compound is a compound represented by formula (I), or a pharmaceut...  
WO/2018/122232A1
Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.  
WO/2018/124528A1
The present invention relates to a method for preparing thiamine dilauryl sulfate without using an organic solvent, and more particularly to a method for preparing thiamine dilauryl sulfate of high purity without using an organic solvent...  
WO/2018/125992A1
Compounds that may inhibit Oplophorus-derived luciferases are disclosed as well as compositions and kits comprising the compounds, and methods of using the compounds.  
WO/2018/116836A1
The purpose of the present invention is to provide a method for industrially advantageously producing a high-purity polymerizable compound. The method of the present invention is for producing a polymerizable compound represented by form...  
WO/2018/119441A1
The present disclosure relates to bifunctional compounds, which find utility as modulators of receptor tyrosine kinase (RTK) proteins. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end ...  
WO/2018/116285A1
The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, R1, R2, R3, X1, X2, m and n are as defined herein, which are active as modulators of retinoid-related orphan re...  
WO/2018/118868A1
The present invention relates to compounds of formula (I'), tautomers, stereoisomers, and pharmaceutically acceptable salts thereof, to processes for their preparation, to pharmaceutical formulations containing such compounds and to thei...  
WO/2018/115218A1
The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substan...  
WO/2018/119448A1
The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directe...  
WO/2018/114596A1
The invention relates to substituted heteroaryl pyrrolones of general formula (I) and salts thereof, wherein the groups of general formula (I) are defined as cited in the description, and to the use thereof as herbicides, in particular f...  
WO/2018/115591A1
Compounds of formula (I) wherein R1, R2,R3,R4,R5,R23,R24,L, A and Bare as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1(...  
WO/2018/119080A1
The present disclosure describes novel methods for treating a subject with a hepatic disorder. Specifically, the methods include the administration of an S1P1-selective agent to a subject in order to stimulate liver tissue development, v...  
WO/2018/114670A1
The present invention covers [4-(phenylsulfonyl)piperazin-1-yl](1H-1,2,3-triazol-4- yl)methanone compounds of general formula (I): (I), in which Q, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, interme...  
WO/2018/119036A1
Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) wherein R1, R2, R3, R4, R5, R6, ...  
WO/2018/119357A1
The present disclosure relates to bifunctional compounds, which find utility as modulators of enhancer of zeste homolog 2 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one...  
WO/2018/118705A1
The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.  
WO/2018/115275A1
The present invention relates to a class of novel heterocyclic compounds, to pharmaceutical compositions comprising the compounds and their use in the treatment of kinetoplastid infections.  
WO/2018/118781A1
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein R1, A, and J are as defined in the disclosure. Also disclosed are compositions containing the compounds of F...  
WO/2018/116108A1
Provided are IDO inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.  
WO/2018/116281A1
The disclosure provides a process of making the compound of Formula I, and pharmaceutically acceptable salts thereof: and the process of making the intermediate of Formula III: wherein PG is as defined as set forth in the specification.  
WO/2018/117166A1
The present invention addresses the problem of providing: a novel thiazole derivative or a pharmacologically acceptable salt thereof; a pharmaceutical composition which contains the thiazole derivative or a pharmacologically acceptable s...  
WO/2018/116107A1
Provided are IDO inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases ...  
WO/2018/114662A1
The invention relates to substituted 1,2,4-thiadiazolyl pyrrolones and 1,2,4-thiadiazolyl hydantoins of general formula (I) and salts thereof, wherein the groups of general formula (I) are defined as cited in the description, and to the ...  
WO/2018/118384A1
Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, wherein R1, R2, R3, R4, R5, R6, J2, Q1, Q2, T and Y are as defined in the disclosure. Also disclosed are compositions containing the compound...  
WO/2018/118827A1
The present invention is directed to compounds of Formula I, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the tr...  
WO/2018/114781A1
The present invention provides compounds having Ar-V7 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention a...  
WO/2018/115064A1
The present invention relates to new compounds of formula (I): showing great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1subunit of voltage-gated calcium channels or dua...  
WO/2018/119183A2
Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.  
WO/2018/111012A1
The present invention relates to the compounds according to Formula (I), the racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions comprising these, for the treatment or ...  
WO/2018/109643A1
The present invention relates to bisaryl heterocycle compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to bisaryl heterocycles of Formula...  
WO/2018/112136A1
The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other -threonine kinase mediated diseases, having the Formula: (I) wherein A, L, R1, R2, R3, and n are described herein.  
WO/2018/111893A1
The present invention concerns novel deuterated and non-deuterated cyclic chemical compounds and their corresponding salts thereof active on protein kinases in general, and in particular as inhibitors of protein kinases. Additionally, me...  

Matches 1 - 50 out of 36,462